Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Impact · against what's priced in

Retension Pharmaceuticals (RTSN) successfully raised $45 million through an upsized IPO to fund late-stage clinical trials for RTN-001. This provides the necessary capital to advance the drug through Phase 2b and into Phase 3 for uncontrolled hypertension.

RTSN+0.80: No priced-in read yet
In context: The company has secured $45 million in gross proceeds via an upsized IPO to fund the completion of its Phase 2b trial and the preparation for a Phase 3 trial of RTN-001.
Read from the article alone

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

healthcare
pharmaceuticals
ipo
RTSN
SNY
biotechnology
cardiovascular
clinical trials
hypertension
nasdaq

Search tags

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

What matters in this story

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

What matters in this story

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

What matters in this story

Next reads from the same story arc

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

What matters in this story

Next reads from the same story arc

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

How each ticker is affected

Connected tickers

Track these names every morning.

AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD

Lycia Therapeutics Launches U.S. IPO For Food Allergy, Graves' Disease Pipeline

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL